The introduction of exa-cel as a gene-editing therapy marks a significant advance in treating hemoglobinopathies, offering new hope for patients with SCD and β-thalassemia. This treatment focuses on reactivating fetal hemoglobin to mitigate disease symptoms effectively.

The intersection of personal life and professional obligations is recounted by Dr. Tessa Adžemović, who discusses the profound impact of personal relationships on her residency experience and patient interactions.

Ozempic, commonly used off-label for weight management, can cause significant facial side effects, termed “Ozempic face,” marked by increased wrinkling and loss of skin elasticity.

Recent findings demonstrate a 74% first-attempt success rate for neonatal intubation using video laryngoscopy, compared to 45% with direct laryngoscopy. This method not only improves outcomes but also reduces the median number of intubation attempts, reinforcing its value in neonatal emergency care.

Brazzein, now FDA-approved, emerges as a zero-calorie sweetener potentially safe for diabetic and obese populations, requiring further study to validate its health impacts.

This study from Cleveland Clinic highlights a counterintuitive trend where higher numbers of COVID-19 vaccine doses could lead to increased risk of infection, underscoring the complexity of immune responses and vaccine effectiveness over time.